| Old Articles: <Older 6101-6110 Newer> |
 |
The Motley Fool December 24, 2009 Brian Orelli |
Another Reason to Worry About Pfizer The FDA fails to approve Lyrica for treating anxiety.  |
The Motley Fool December 23, 2009 Brian Orelli |
Cancer Isn't Merck's Biggest Problem There's still hope for Merck's Vytorin, but investors will have to wait.  |
The Motley Fool December 23, 2009 Brian Orelli |
2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.  |
The Motley Fool December 22, 2009 Brian Orelli |
This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis.  |
The Motley Fool December 22, 2009 Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year  |
The Motley Fool December 22, 2009 Brian Orelli |
Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.  |
The Motley Fool December 22, 2009 Brian Orelli |
2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes."  |
The Motley Fool December 18, 2009 Brian Orelli |
Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.  |
The Motley Fool December 18, 2009 Brian Orelli |
2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.  |
The Motley Fool December 18, 2009 Brian Orelli |
Buy a Company, Get the Plant for Free Earlier this year, Merck company bought a pipeline of follow-on biologics (and a manufacturing plant to make them in) from Insmed. Now it's back for more with an acquisition of Avecia Biologics.  |
| <Older 6101-6110 Newer> Return to current articles. |